Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Expert Opinion on Drug Safety|May 25, 2017
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studiesDaniel Castellano, José Pablo Maroto, Enrique Espinosa, et al.
Scientific Reports|March 12, 2026
Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre studyArturo Llobell-Uriel, Íñigo González-Mazón, Jordi Gratacós, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2022
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trialJoan Carles, Teresa Alonso-Gordoa, Begoña Mellado, et al.
Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
Targeted Oncology|January 30, 2019
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)Albert Font, Raquel Luque, José Carlos Villa, et al.
Pharmacogenomics|March 30, 2016
SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinomaIgnacio Duran, Carlos Hagen, José Ángel Arranz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate CancerCora Sternberg, Andrew Armstrong, Roberto Pili, et al.
European Urology|January 18, 2025
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety AnalysisSilke Gillessen, Bertrand Tombal, Fabio Turco, et al.
The Lancet. Oncology|April 9, 2017
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trialJesus García-Donas, Albert Font, Begoña Pérez-Valderrama, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 17, 2025
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'Ignacio Peláez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, et al.
Pageof 7